Skip to main content

Articles

Page 1 of 16

  1. Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce.

    Authors: Alessandro Cozzi-Lepri, Lars Peters, Annegret Pelchen-Matthews, Bastian Neesgaard, Stephane De Wit, Isik Somuncu Johansen, Simon Edwards, Christoph Stephan, Georgios Adamis, Therese Staub, Alexandra Zagalo, Pere Domingo, Daniel Elbirt, Katharina Kusejko, Johanna Brännström, Dzmitry Paduta…
    Citation: AIDS Research and Therapy 2022 19:38
  2. Polypharmacy in people living with HIV/AIDS (PLWHA) is a rising morbidity that exacts hefty economic burden on health budgets in addition to other adverse clinical outcomes. Despite recent advances, uncertaint...

    Authors: Mohammed Ibn-Mas’ud Danjuma, Safah Khan, Farah Wahbeh, Lina Mohammad Naseralallah, Unwam E. Jumbo and Abdelnaser Elzouki
    Citation: AIDS Research and Therapy 2022 19:37
  3. We describe a case of a 30-year-old MSM recently diagnosed with HIV, immunocompromised with a purplish or brown rash all over the body for 3 to 4 months. The histopathology of the cutaneous lesions and pleural...

    Authors: Sampada Bangar, Rohit Vashisht, Pratiksha Sonar, Kunal Ghule, Leena Rawat, Arati Mane, Abhijit Kadam, Nomita Chandhiok and Seema Sahay
    Citation: AIDS Research and Therapy 2022 19:36
  4. Strategies to support adherence are constrained by the lack of tools to objectively monitor medication intake in low-resource settings. Pharmacologic measures are objective, but pharmacy refill data is more ac...

    Authors: Jacinta N. Nwogu, Samuel O. Ngene, Chinedum P. Babalola, Adeniyi Olagunju, Andrew Owen, Saye H. Khoo, Olayinka A. Kotila, Baiba Berzins, Hideaki Okochi, Regina Tallerico, Monica Gandhi and Babafemi Taiwo
    Citation: AIDS Research and Therapy 2022 19:35
  5. Since the scale-up of routine viral load (VL) testing started in 2016, there is limited evidence on VL suppression rates under programmatic settings and groups at risk of non-suppression. We conducted a study ...

    Authors: Trudy Tholakele Mhlanga, Bart K. M. Jacobs, Tom Decroo, Emma Govere, Hilda Bara, Prosper Chonzi, Ngwarai Sithole, Tsitsi Apollo, Wim Van Damme, Simbarashe Rusakaniko, Lutgarde Lynen and Richard Makurumidze
    Citation: AIDS Research and Therapy 2022 19:34
  6. Multi-types COVID-19 vaccines have shown safety and efficacy against COVID-19 in adults. Although current guidelines encourage people living with HIV (PLWH) to take COVID-19 vaccines, whether their immune resp...

    Authors: Shi Zou, Mengmeng Wu, Fangzhao Ming, Songjie Wu, Wei Guo, Gifty Marley, Zhongyuan Xing, Zhiyue Zhang, Minxia Zeng, Chao Sun, Jianfeng Zhang, Weiming Tang and Ke Liang
    Citation: AIDS Research and Therapy 2022 19:33
  7. This study investigated prevalence trends and identified the associated factors of HIV, syphilis and hepatitis C virus (HCV) among pregnant women in the Guangxi Zhuang Autonomous Region (Guangxi), Southwest Ch...

    Authors: Shanmei Zhong, Yanyun Ou, Fei Zhang, Zhaosen Lin, Rongye Huang, Aidan Nong, Zhenxian Wu, Huayue Liang, Cai Qin, Qiuyu Wei, Yuan Yang, Dee Yu, Xianyan Tang, Li Ye, Deping Liu, Hao Liang…
    Citation: AIDS Research and Therapy 2022 19:31
  8. Understanding the experiences, needs, preferences, and behaviors of people living with HIV (PLHIV) are critical to tailor HIV treatment. However, there is limited empirical evidence in Ethiopia on the views of...

    Authors: Yihalem Abebe Belay, Mezgebu Yitayal, Asmamaw Atnafu and Fitalew Agimass Taye
    Citation: AIDS Research and Therapy 2022 19:30
  9. There is no other better way to safeguard an infant’s health in the first 6 months of life than exclusive breastfeeding (EBF). Breast milk is valuable in all aspects of an infant’s physical and mental growth a...

    Authors: Rose Faustine and Fabiola Vincent Moshi
    Citation: AIDS Research and Therapy 2022 19:29
  10. Pre-exposure prophylaxis (PrEP) represents a proven biomedical strategy to prevent HIV transmissions among men who have sex with men (MSM) in the United States (US). Despite the design and implementation of va...

    Authors: Ying Wang, Jason W. Mitchell, Chen Zhang and Yu Liu
    Citation: AIDS Research and Therapy 2022 19:28
  11. It has been widely noted that lifetime adherence to antiretroviral therapy (ART) is necessary for HIV treatment outcome; however, retention on ART among people living with HIV (PLWH) remains a great challenge ...

    Authors: Philomena J. Strother, Mathuros Tipayamongkholgul, Varakorn Kosaisevee and Nawarat Suwannapong
    Citation: AIDS Research and Therapy 2022 19:27
  12. We conducted a pilot trial of an intervention targeting intersectional stigma related to being pregnant and living with HIV while promoting capabilities for achieving ‘respected motherhood’ (‘what matters most...

    Authors: Lawrence H. Yang, Evan L. Eschliman, Haitisha Mehta, Supriya Misra, Ohemaa B. Poku, Patlo Entaile, Timothy D. Becker, Tadele Melese, Merrian J. Brooks, Marlene Eisenberg, Melissa A. Stockton, Karen Choe, Danielle Tal, Tingyu Li, Vivian F. Go, Bruce G. Link…
    Citation: AIDS Research and Therapy 2022 19:26
  13. Routine screening for HIV and other sexually transmitted infections (STIs) facilitates early diagnosis and treatment, thereby preventing morbidity and onward transmission. We estimated the prevalence of prior ...

    Authors: Trevor A. Crowell, Sorachai Nitayaphan, Narongrid Sirisopana, Tanyaporn Wansom, Suchai Kitsiripornchai, Leilani Francisco, Qun Li, Nicole Dear, Robert J. O’Connell, Punnee Pitisuttithum and Sandhya Vasan
    Citation: AIDS Research and Therapy 2022 19:25
  14. Evidence on health-related quality of life (HRQoL) outcomes is limited for new antiretroviral therapies (ART). Dolutegravir-based treatment is being rolled out as the preferred first-line treatment for HIV in ...

    Authors: Perez Nicholas Ochanda, Mohammed Lamorde, Kenneth Kintu, Duolao Wang, Tao Chen, Thokozile Malaba, Landon Myer, Catriona Waitt, Helen Reynolds and Saye Khoo
    Citation: AIDS Research and Therapy 2022 19:24
  15. People living with HIV (PLWHIV) commencing antiretroviral therapy (ART) in sub-Saharan Africa experience significant mortality within the first year. Previously, identified risk factors for mortality may be bi...

    Authors: Bradley W. Byers, Douglas Drak, Tinei Shamu, Cleophas Chimbetete, Rumbi Dahwa and David M. Gracey
    Citation: AIDS Research and Therapy 2022 19:23
  16. The initial cases of COVID-19 appeared in December 2019 and Spain was one of the most affected countries during the first wave (March to June). Since then, HIV HGM BioBank has been restructured as an establish...

    Authors: Consuegra Irene, Mauleón Elba, José Luis Jiménez, María José Mellado and María Ángeles Muñoz-Fernández
    Citation: AIDS Research and Therapy 2022 19:22
  17. Viral suppression remains the most desired outcome in the management of patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and this can be achieved by an effective Antire...

    Authors: Stephen Opoku, Samuel Asamoah Sakyi, Nana Kwame Ayisi-Boateng, Anthony Kwame Enimil, Ebenezer Senu, Richard Owusu Ansah, Bismark Dankwah Aning, Diana Atsieno Ojuang, Doreen Nafula Wekesa, Fatima Osman Ahmed, Chidinma B. Okeke and Ama Darkoaa Sarfo
    Citation: AIDS Research and Therapy 2022 19:21
  18. Cryptococcal meningitis (CM) associated immune reconstitution inflammatory syndrome (CM-IRIS) is the second most common complication in HIV-infected individuals with cryptococcal meningitis, with a reported mo...

    Authors: Xiaoxu Han, Hui Liu, Yuqi Wang, Peng Wang, Xin Wang, Yunyun Yi and Xin Li
    Citation: AIDS Research and Therapy 2022 19:20
  19. Intestinal parasites and HIV/AIDS co-infection become a major public health concern in Africa. The management and care of HIV/AIDS patients is being complicated by intestinal parasitic infections. Therefore, t...

    Authors: Daniel Getacher Feleke, Abdurahaman Ali, Habtye Bisetegn and Mengaye Andualem
    Citation: AIDS Research and Therapy 2022 19:19
  20. In low income countries such as Uganda progress has been made towards achieving the United Nations AIDS programme 95-95-95 target however efforts are still impeded by pretreatment drug resistance and adverse d...

    Authors: Angella Namulindwa, John Hans Wasswa, Winnie Muyindike, Robert Tamukong and Joseph Oloro
    Citation: AIDS Research and Therapy 2022 19:18
  21. Medication adherence plays a pivotal role in achieving the desired treatment outcomes. The proportion of HIV patients on second-line antiretroviral therapy is becoming a growing public health concern. However,...

    Authors: Shambel Wedajo, Getu Degu, Amare Deribew and Fentie Ambaw
    Citation: AIDS Research and Therapy 2022 19:17
  22. Cytomegalovirus (CMV) has been linked with cardiovascular disease (CVD) in populations where some individuals are seronegative. However, effects of CMV are unclear in HIV patients who all have high levels of C...

    Authors: Ibnu A. Ariyanto, Riwanti Estiasari, Birry Karim, Ika Praseya Wijaya, Budiman Bela, Amin Soebandrio, Patricia Price and Silvia Lee
    Citation: AIDS Research and Therapy 2022 19:16
  23. Thanks to direct-acting antivirals, hepatitis C virus (HCV) infection can be cured, with similar rates in HCV-infected and HIV–HCV co-infected patients. HCV cure is likely to foster behavioral changes in psych...

    Authors: Tangui Barré, Patrick Mercié, Caroline Lions, Patrick Miailhes, David Zucman, Hugues Aumaître, Laure Esterle, Philippe Sogni, Patrizia Carrieri, Dominique Salmon-Céron and Fabienne Marcellin
    Citation: AIDS Research and Therapy 2022 19:15
  24. The authors recently performed plastic surgeries for a small number of patients with hemophilia, HIV infection, and morphologic evidence of lipodystrophy. Because the pathophysiological mechanism of HIV-associ...

    Authors: Takanobu Mashiko, Kunihisa Tsukada, Hitomi Takada, Szu-Hsien Wu, Koji Kanayama, Rintaro Asahi, Masanori Mori, Akira Kurisaki, Shinichi Oka and Kotaro Yoshimura
    Citation: AIDS Research and Therapy 2022 19:14
  25. Patient preferences for long-acting antiretroviral therapies (LA-ART) should inform development of regimens with optimal adherence and acceptability. We describe a systematic process used to identify attribute...

    Authors: Aaron T. Brah, Douglas Barthold, Brett Hauber, Ann C. Collier, Rodney J. Y. Ho, Vincent C. Marconi, Jane M. Simoni and Susan M. Graham
    Citation: AIDS Research and Therapy 2022 19:13
  26. Pre-Exposure Prophylaxis (PrEP) has demonstrated efficacy in the reduction of sexually transmitted HIV infections. The prolonged use of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) co-formulatio...

    Authors: Karla Cristina Silva Petruccelli, Djane Clarys Baía-da-Silva, Fernando Val, Monica Santos Valões, Nadia Cubas-Vega, Alexandre Vilhena Silva-Neto, Vanderson Sampaio, Aline Alencar, Roberto Pecoits-Filho, Rodrigo Carvalho Moreira, Sandra Wagner Cardoso, Ronaldo I. Moreira, Iuri Costa Leite, José Valdez Madruga, Esper G. Kallas, Paulo R. Alencastro…
    Citation: AIDS Research and Therapy 2022 19:12
  27. In Nigeria, private for-profit health facilities present an opportunity to achieve the UNAIDS 95-95-95 HIV targets because of their reach and patronage. However, little is known about determinants of outcomes ...

    Authors: Muyi Aina, Zeena Yesufu, Abdulateef Salisu, Echezona Ezeanolue, Charles Mensah and Patrick Dakum
    Citation: AIDS Research and Therapy 2022 19:11
  28. Zambia recently achieved UNAIDS 90-90-90 treatment targets for HIV epidemic control; however, inpatient facilities continue to face a large burden of patients with advanced HIV disease and HIV-related mortalit...

    Authors: Nyuma Mbewe, Michael J. Vinikoor, Sombo Fwoloshi, Mundia Mwitumwa, Shabir Lakhi, Suilanji Sivile, Mallika Yavatkar, Brianna Lindsay, Kristen Stafford, Lottie Hachaambwa, Lloyd Mulenga and Cassidy W. Claassen
    Citation: AIDS Research and Therapy 2022 19:10
  29. Estimating the population sizes of key populations(people who inject drugs, men who have sex with men, transgender persons, and commercial sex workers) is critical for understanding the overall Human Immunodef...

    Authors: Chen Xu, Fengshi Jing, Ying Lu, Yuxin Ni, Joseph Tucker, Dan Wu, Yi Zhou, Jason Ong, Qingpeng Zhang and Weiming Tang
    Citation: AIDS Research and Therapy 2022 19:9
  30. Infant antiretroviral prophylaxis has an important role in reduction of Human immune virus transmission from mother to child during the postpartum period. Male partner involvement was considered as a priority ...

    Authors: Tamirat Melis and Yohannes Fikadu
    Citation: AIDS Research and Therapy 2022 19:8
  31. Support groups for people living with the Human Immunodeficiency Virus (HIV) have continued to evolve since their emergence over two decades ago. In addition to providing HIV education and fostering psychosoci...

    Authors: Fine Mazambara, Dexter Chagwena, Tinashe Mudzviti, Samantha Sithole, Tsitsi Monera-Penduka, Charles C. Maponga and Gene D. Morse
    Citation: AIDS Research and Therapy 2022 19:7
  32. In hospitalized people with HIV (PWH) there is an increased risk of mortality from COVID-19 among hospitalized PWH as compared to HIV-negative individuals. Evidence suggests that tocilizumab—a humanized monocl...

    Authors: Samuel J. Minkove, Grant Geiger, Josep M. Llibre, Mary W. Montgomery, Natalie E. West, Natasha M. Chida, Annukka A. R. Antar, Dima Dandachi and Ethel D. Weld
    Citation: AIDS Research and Therapy 2022 19:6
  33. Maintaining optimal adherence and viral suppression in people living with HIV (PLWH) is essential to ensure both preventative and therapeutic benefits of antiretroviral therapy (ART). Prisoners bear a particul...

    Authors: Terefe Gone Fuge, George Tsourtos and Emma R. Miller
    Citation: AIDS Research and Therapy 2022 19:5
  34. Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed effica...

    Authors: Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouzé Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier and François Raffi
    Citation: AIDS Research and Therapy 2022 19:4
  35. Data on the association of human immunodeficiency virus (HIV) infection with adverse outcomes in patients with COVID-19 are conflicting. This systematic review and meta-analysis aimed to summarize the availabl...

    Authors: Celestin Danwang, Jean Jacques Noubiap, Annie Robert and Jean Cyr Yombi
    Citation: AIDS Research and Therapy 2022 19:3
  36. We developed a personalized Monocyte-Derived Dendritic-cell Therapy (MDDCT) for HIV-infected individuals on suppressive antiretroviral treatment and evaluated HIV-specific T-cell responses.

    Authors: Marcella Vassão de Almeida Baptista, Laís Teodoro da Silva, Sadia Samer, Telma Miyuki Oshiro, Iart Luca Shytaj, Leila B. Giron, Nathalia Mantovani Pena, Nicolly Cruz, Gisele Cristina Gosuen, Paulo Roberto Abrão Ferreira, Edécio Cunha-Neto, Juliana Galinskas, Danilo Dias, Maria Cecilia Araripe Sucupira, Cesar de Almeida-Neto, Reinaldo Salomão…
    Citation: AIDS Research and Therapy 2022 19:2
  37. Retention in clinical care is important for people living with HIV (PLWH). Evidence suggests that missed clinic visits are associated with interruptions in antiretroviral therapy (ART), lower CD4 counts, virol...

    Authors: Nicole Dear, Allahna Esber, Michael Iroezindu, Emmanuel Bahemana, Hannah Kibuuka, Jonah Maswai, John Owuoth, Christina S. Polyak, Julie A. Ake and Trevor A. Crowell
    Citation: AIDS Research and Therapy 2022 19:1
  38. In 2018, approximately 1.6 million adolescents (aged 10–19) were living with HIV worldwide, with the highest HIV prevalence found in Eswatini. Adolescents and young adults living with HIV are a vulnerable popu...

    Authors: Tara E. Ness, Vedika Agrawal, Danielle Guffey, Amanda Small, Tandzile Simelane, Sandile Dlamini, Jaime Petrus and Bhekumusa Lukhele
    Citation: AIDS Research and Therapy 2021 18:100
  39. Ethiopia, being in the Sub Saharan region of Africa, is one of the countries with a substantial burden of HIV infection. Because of the high burden of HIV and poor health care settings, HAND is prevalent as de...

    Authors: Yosef Zenebe, Baye Akele, Mulugeta W/Selassie and Mogesie Necho
    Citation: AIDS Research and Therapy 2021 18:99
  40. Adolescents are at increased risk of HIV infection compared to other age groups. There is an urgent need for strategic information that will inform programmes to reduce risk and vulnerability to HIV and revers...

    Authors: Musawenkosi Mabaso, Goitseone Maseko, Ronel Sewpaul, Inbarani Naidoo, Sean Jooste, Sinovuyo Takatshana, Tarylee Reddy, Khangelani Zuma and Nompumelelo Zungu
    Citation: AIDS Research and Therapy 2021 18:97
  41. Late presentation to HIV/AIDS care presents serious health concerns, like increased transmission and high healthcare costs, increased mortality, early development of opportunistic infection, increased risk of ...

    Authors: Chengqing Sun, Jianjun Li, Xiaoyan Liu, Zhi Zhang, Tao Qiu, Haiyang Hu, You Wang and Gengfeng Fu
    Citation: AIDS Research and Therapy 2021 18:96
  42. AIDS as a human crisis may lead to devastating psychological trauma and stress for patients. Therefore, it is necessary to study different aspects of their lives for better support and care. Accordingly, this ...

    Authors: Behzad Imani, Shirdel Zandi, Salman khazaei and Mohamad Mirzaei
    Citation: AIDS Research and Therapy 2021 18:95
  43. Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alaf...

    Authors: Kensuke Abe, Taku Obara, Satomi Kamio, Asahi Kondo, Junji Imamura, Tatsuya Goto, Toshihiro Ito, Hiroshi Sato and Nobuyuki Takahashi
    Citation: AIDS Research and Therapy 2021 18:94
  44. Anti-retroviral therapy regimen discontinuations become a big challenge and cause diminishing the clinical and immunological benefit of treatment in Ethiopia. It reduces both the duration and the chance of vir...

    Authors: Tewodros Getnet Amera, Kassawmar Angaw Bogale and Yibekal Manaye Tefera
    Citation: AIDS Research and Therapy 2021 18:93
  45. This study aims to evaluate the safety of inactivated COVID-19 vaccine among adult people living with HIV (PLWH). In total, 259 PLWH who received at least one dose of inactivated COVID-19 vaccine were enrolled...

    Authors: Songjie Wu, Yubin Zhang, Fangzhao Ming, Shi Zou, Mengmeng Wu, Wei Guo, Weiming Tang and Ke Liang
    Citation: AIDS Research and Therapy 2021 18:92
  46. Adolescents are lagging behind in the “third 95” objective of the Joint United Nations Program on HIV/AIDS requiring 95% of individuals on antiretroviral therapy (ART) to have viral load (VL) suppression. This...

    Authors: Joel Maena, Aduragbemi Banke-Thomas, Nelson Mukiza, Cynthia Ndikuno Kuteesa, Ronald Makanga Kakumba, Hajira Kataike, Samuel Kizito, Juliet Allen Babirye and Rita Nakalega
    Citation: AIDS Research and Therapy 2021 18:91
  47. Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced human immunodeficiency virus (HIV) infection. Effective antiretr...

    Authors: Keiji Konishi, Hidenori Nakagawa, Akio Nakahira, Takahiro Okuno, Takeshi Inoue and Michinori Shirano
    Citation: AIDS Research and Therapy 2021 18:90
  48. Increased availability of HIV care over the past decade has dramatically reduced morbidity and mortality among people living with HIV (PLWH) in sub-Saharan Africa. However, perceived and experienced barriers t...

    Authors: Nancy Somi, Nicole Dear, Domonique Reed, Ajay Parikh, Anange Lwilla, Emmanuel Bahemana, Samoel Khamadi, Michael Iroezindu, Hannah Kibuuka, Jonah Maswai, Trevor A. Crowell, John Owuoth, Lucas Maganga, Christina Polyak, Julie Ake and Allahna Esber
    Citation: AIDS Research and Therapy 2021 18:89